CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Positron Emission Tomography–Computed Tomography for Patients with Suspected or Confirmed Coronary Artery Disease: Clinical Utility, Cost-Effectiveness, and Diagnostic Accuracy

Last updated: October 19, 2020
Project Number: RA1141-000
Product Line: Rapid Response
Research Type: Device
Report Type: Reference List
Result type: Report

Question

  1. What is the clinical utility of positron emission tomography–computed tomography in patients to detect coronary artery disease and to measure coronary flow reserve?
  2. What is the cost-effectiveness of positron emission tomography–computed tomography in patients to detect coronary artery disease and to measure coronary flow reserve?
  3. What is the clinical evidence regarding the safety of positron emission tomography–computed tomography in patients to detect coronary artery disease and to measure coronary flow reserve?
  4. What is the diagnostic accuracy of positron emission tomography–computed tomography in patients to detect coronary artery disease and to measure coronary flow reserve?

Key Message

One randomized controlled trial and one non-randomized study were identified regarding the clinical utility of positron emission tomography–computed tomography in patients to detect coronary artery disease and to measure coronary flow reserve. In addition, three systematic reviews (two with meta-analyses) and 14 non-randomized studies were identified regarding the diagnostic accuracy of positron emission tomography–computed tomography in patients to detect coronary artery disease and to measure coronary flow reserve. One of the non-randomized studies also addressed the safety of positron emission tomography–computed tomography in patients to detect coronary artery disease and to measure coronary flow reserve. No relevant literature was identified regarding the cost-effectiveness of positron emission tomography–computed tomography in patients to detect coronary artery disease and to measure coronary flow reserve.